Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate After Dual and Triple Therapy in Spain: A Sub-Study of the ORESTES Study

Abstract Introduction Chronic obstructive pulmonary disease (COPD) is a progressive lung condition associated with high morbidity and mortality. Single-inhaler triple therapy (SITT), such as budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF), is recommended for patients with COPD who are...

詳細記述

書誌詳細

主要な著者:	Juan Marco Figueira-Gonçalves, Bernardino Alcázar-Navarrete, Raquel Casitas-Mateo, Jessica González, Carolina María Gotera-Rivera, Alberto Herrejón-Silvestre, Juan Margallo-Iribarnegaray, Marta Martín-Lana, Abel Pallarés-Sanmartín, Sergi Pascual-Guardia, Alberto Saura-Vinuesa, Carmen Corregidor-García, Eunice Fitas, Joaquín Sánchez-Covisa
フォーマット:	Artigo
言語:	Inglês
出版事項:	Adis, Springer Healthcare 2026-01-01
シリーズ:	Pulmonary Therapy
主題:	Budesonide/glycopyrronium/formoterol fumarate dihydrate Chronic obstructive pulmonary disease COPD Treatment pathway Exacerbations Real-world evidence
オンライン･アクセス:	https://doi.org/10.1007/s41030-026-00341-6
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!